TELA Bio, Inc. (TELA)

Over the past six months, TELA Bio's stock price has been impacted by several events. The Q3 2025 earnings report revealed a revenue increase but missed forecasts, leading to initial stock decline followed by a partial recovery. Stock offerings were priced in November and December 2025. Analyst ratings were updated with lowered price targets due to sales issues and lower average selling prices. A new credit facility was secured from Perceptive Advisors. Leadership changes included the appointment of Jeffrey Blizard as President and Gregory Firestone as Chief Commercial Officer.

The provided search results do not explicitly state a specific demand seasonality for TELA Bio's products and services. Demand could potentially be influenced by factors such as patient elective surgery schedules, insurance deductibles resetting, and holiday periods.

TELA Bio, Inc. is a medical technology company focused on regenerative medicine and advanced soft tissue repair solutions. Their core business revolves around providing innovative soft-tissue reconstruction solutions that aim to optimize clinical outcomes. The company's product portfolio integrates proprietary biomaterials and processing technologies, including acellular dermal matrices, hemostatic agents, and tissue scaffold systems. Major products include OviTex Reinforced Tissue Matrix, OviTex PRS Reinforced Tissue Matrix, OviTex for Laparoscopic and Robotic Procedures, and LIQUIFIX Fixation Technology. In 2023, TELA Bio acquired Novus Scientific AB, adding the TIGR Matrix product line.

TELA Bio primarily markets its products through a direct sales force in the United States. The company is also actively expanding its international presence, notably with the European commercial launch of OviTex Inguinal for robotic and laparoscopic hernia repair. TELA Bio has reported significant market share gains in the UK, Germany, Netherlands, Austria, and Switzerland, with promising early results in Spain and Portugal.

TELA Bio's brand reputation is built on its commitment to improving patient outcomes in soft-tissue reconstruction by leveraging the body's natural healing response and minimizing the use of permanent synthetic materials. Cybersecurity events affecting hospital customers caused disruptions in Q2 2024. Financial performance has shown revenue growth but faces profitability challenges. Sales force restructuring and leadership changes have been implemented to address declining average selling prices and competitive challenges.

The ownership structure of TELA Bio, Inc. is largely dominated by institutional funds and a significant insider-affiliated investor, collectively holding over 60% of the company's common stock. Major institutional owners include Nantahala Capital Management, LLC, Essex Woodlands Management, Inc., Silverarc Capital Management, LLC, Stonepine Capital Management, LLC, Vanguard Group Inc, UBS Group AG, DAFNA Capital Management LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Perkins Capital Management Inc, and Citigroup Inc. EW Healthcare Partners represents a major shareholder/insider-affiliated category. As of February 3, 2026, 55 institutional owners held a total of 25,469,242 shares.